Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy.
Levati L, Tabolacci C, Facchiano A, Facchiano F, Alvino E, Antonini Cappellini GC, Scala E, Bonmassar L, Caporali S, Lacal PM, Bresin A, De Galitiis F, Russo G, D'Atri S. Levati L, et al. Among authors: alvino e. J Exp Clin Cancer Res. 2024 Aug 15;43(1):226. doi: 10.1186/s13046-024-03151-3. J Exp Clin Cancer Res. 2024. PMID: 39143551 Free PMC article.
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.
Levati L, Bassi C, Mastroeni S, Lupini L, Antonini Cappellini GC, Bonmassar L, Alvino E, Caporali S, Lacal PM, Narducci MG, Molineris I, De Galitiis F, Negrini M, Russo G, D'Atri S. Levati L, et al. Among authors: alvino e. Cancers (Basel). 2022 Jul 29;14(15):3706. doi: 10.3390/cancers14153706. Cancers (Basel). 2022. PMID: 35954369 Free PMC article.
Loss of miR-204 expression is a key event in melanoma.
Galasso M, Morrison C, Minotti L, Corrà F, Zerbinati C, Agnoletto C, Baldassari F, Fassan M, Bartolazzi A, Vecchione A, Nuovo GJ, Di Leva G, D'Atri S, Alvino E, Previati M, Nickoloff BJ, Croce CM, Volinia S. Galasso M, et al. Among authors: alvino e. Mol Cancer. 2018 Mar 9;17(1):71. doi: 10.1186/s12943-018-0819-8. Mol Cancer. 2018. PMID: 29523154 Free PMC article.
Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.
Caporali S, Alvino E, Lacal PM, Ruffini F, Levati L, Bonmassar L, Scoppola A, Marchetti P, Mastroeni S, Antonini Cappellini GC, D'Atri S. Caporali S, et al. Among authors: alvino e. Oncotarget. 2017 Dec 9;8(69):113472-113493. doi: 10.18632/oncotarget.23052. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371923 Free PMC article.
41 results